Controlled Clinical Trial of L-dopa and Nafoxidine in Advanced Breast Cancer: an E.O.R.T.C. Study

Overview

Journal Br Med J

Specialty General Medicine

Date 1975 Jun 28

PMID 1095122

Citations 7

Authors

E ENGELSMAN

J C HEUSON

J Blonk van der Wijst

A DROCHMANS

H Maass

F Cheix

L G Sobrinho

H NOWAKOWSKI

Affiliations

Soon will be listed here.

Abstract

L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.

Citing Articles

Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Boland M, Tatonetti N Pharmacogenomics J. 2016; 16(5):411-29.

PMID: 27401223 PMC: 5028238. DOI: 10.1038/tpj.2016.48.

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.

Bontenbal M, Foekens J, Lamberts S, de Jong F, van Putten W, Braun H Br J Cancer. 1998; 77(1):115-22.

PMID: 9459155 PMC: 2151275. DOI: 10.1038/bjc.1998.18.

Prognostic significance of serum prolactin levels in advanced breast cancer.

Dowsett M, McGarrick G, Harris A, Coombes R, Smith I, Jeffcoate S Br J Cancer. 1983; 47(6):763-9.

PMID: 6860546 PMC: 2011370. DOI: 10.1038/bjc.1983.129.

Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells.

Mira-y-Lopez R, Rifkin D, OSSOWSKI L Proc Natl Acad Sci U S A. 1986; 83(20):7780-4.

PMID: 3463998 PMC: 386805. DOI: 10.1073/pnas.83.20.7780.

Season of tumour detection influences factors predicting survival of patients with breast cancer.

Mason B, Holdaway I, Stewart A, Neave L, Kay R Breast Cancer Res Treat. 1990; 15(1):27-37.

PMID: 2328328 DOI: 10.1007/BF01811887.

References

Malarkey W, Jacobs L, Daughaday W . Levodopa suppression of prolactin in nonpuerperal galactorrhea. N Engl J Med. 1971; 285(21):1160-3. DOI: 10.1056/NEJM197111182852102. View

KWA H, ENGELSMAN E, Cleton F . Plasma-prolactin in human breast cancer. Lancet. 1974; 1(7855):433-5. DOI: 10.1016/s0140-6736(74)92385-x. View

STOLL B . Brain catecholamines and breast cancer: a hypothesis. Lancet. 1972; 1(7747):431. DOI: 10.1016/s0140-6736(72)90875-6. View

MINTON J, Dickey R . Prolactin, F.S.H., and L.H. in breast cancer: effect of levodopa and oophorectomy. Lancet. 1972; 1(7759):1069-70. DOI: 10.1016/s0140-6736(72)91249-4. View

Rozencweig M, HEUSON J, Bila S, LHermite M, Robyn C . Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women. Eur J Cancer (1965). 1973; 9(9):657-64. DOI: 10.1016/0014-2964(73)90008-x. View